For the reasons above, the primary objective of our study was to evaluate the effect of MET used in combination with TMZ on EGFR mutation (d2-7) carrying GBM models sensitive and resistant to TMZ and on patient-derived EGFR amplified Cancer Stem Cell line. The gene discussed is EGFR; the disease is cancer.